Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Nature
; 602(7898): 671-675, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1616994
ABSTRACT
The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa1-3. It has since spread to many countries and is expected to rapidly become dominant worldwide. The lineage is characterized by the presence of around 32 mutations in spike-located mostly in the N-terminal domain and the receptor-binding domain-that may enhance viral fitness and enable antibody evasion. Here we isolated an infectious Omicron virus in Belgium from a traveller returning from Egypt. We examined its sensitivity to nine monoclonal antibodies that have been clinically approved or are in development4, and to antibodies present in 115 serum samples from COVID-19 vaccine recipients or individuals who have recovered from COVID-19. Omicron was completely or partially resistant to neutralization by all monoclonal antibodies tested. Sera from recipients of the Pfizer or AstraZeneca vaccine, sampled five months after complete vaccination, barely inhibited Omicron. Sera from COVID-19-convalescent patients collected 6 or 12 months after symptoms displayed low or no neutralizing activity against Omicron. Administration of a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titres 6-fold to 23-fold lower against Omicron compared with those against Delta. Thus, Omicron escapes most therapeutic monoclonal antibodies and, to a large extent, vaccine-elicited antibodies. However, Omicron is neutralized by antibodies generated by a booster vaccine dose.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Imunização Secundária
/
Anticorpos Neutralizantes
/
Evasão da Resposta Imune
/
SARS-CoV-2
/
COVID-19
/
Anticorpos Antivirais
Tipo de estudo:
Estudo prognóstico
/
Ensaios controlados aleatorizados
Tópicos:
Vacinas
/
Variantes
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
País/Região como assunto:
Europa
Idioma:
Inglês
Revista:
Nature
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
S41586-021-04389-z
Similares
MEDLINE
...
LILACS
LIS